Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 432c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($4.32). Revenue for the quarter came in at $37.93 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold
• Catalyst Metals Ltd (CYL:AU) PT Lowered to AUD9.25 at UBS
• Paramount Skydance (PSKY) Reiterated at Market Outperform by Citizens as WBD Close Cleared